🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Amarin Corporation PLC (AMRN)

NASDAQ
Currency in USD
Disclaimer
0.606
+0.013(+1.69%)
Closed
After Hours
0.605-0.001(-0.165%)

AMRN Comments

1.25/30 soon…and 🚀🚀
There are some interesting articles and preprints on researchgate in regards to vascepa as a treatment for long covid
whats happend?
EU approval, nice
Holding April 30 6.50 strike call options for EU approval!
over 20 Dollar end of this year
$8 this week
https://www.investing.com/news/leerink-partners-stick-to-their-buy-rating-for-amarin-corporation-plc-2436922
What Does champ mean
https://investor.amarincorp.com/news-releases/news-release-details/amarin-receives-positive-chmp-opinion-icosapent-ethyl
Amarin Corporation plc (NASDAQ: AMRN) announced that the Chinese Society of Cardiology has included icosapent ethyl in its updated ‘Guidelines for Primary Prevention of Cardiovascular Diseases for 2021'
$8 By Feb. 2021
nice call...where next?
nice call...where next?
https://www.globenewswire.com/news-release/2021/01/07/2154744/0/en/Amarin-Provides-Preliminary-2020-Results-and-2021-Outlook.html this is going to be a pleasant summer I would say
Yeaaah, a very slight wobble ..  great u r   ;-P
Had a slight wobble, I think still likely to be heading upwards.
What happen with this stock? Maybe stock split?
Stock fell down go boom.
https://investor.amarincorp.com/news-releases/news-release-details/amarin-shares-topline-data-partners-pivotal-phase-3-study
Mr. Xin Ni: "VASCEPA has huge commercial potential in the fast-growing Chinese market. We will work with Amarin to submit the new drug application as soon as possible to bring this cross-era innovative drug to China.”
There were approximately 180.4 million hypertriglyceridemia (HTG) patients in China in 2019, representing approximately 20.2% of the adult population
I told you to switch with TEVA
lol $5.57
going to $20 again !??  I'm scared, very
what's causing stock to go down
hopefully stock goes up been beaten up for awhile now
It should go back at least above 7 because Vascepa generics did not lead to a decrease in sales, rather ... an increase? like if customers just want the most technological
... or that the demand is much higher than the supply
agreed!
My congratulations to Amarin for beating all earnings expectations in its third quarter
More important than the one below :  --> VASCEPA® (ICOSAPENT ETHYL) FOUND TO SIGNIFICANTLY REDUCE CARDIOVASCULAR EVENTS IN PATIENTS WITH COMPROMISED RENAL FUNCTION AT BASELINE IN PRESPECIFIED AND POST HOC SUBGROUP ANALYSES OF LANDMARK REDUCE-IT® STUDY
http://investor.amarincorp.com/news-releases/news-release-details/vascepar-icosapent-ethyl-found-significantly-reduce-ischemic
This is meaningful:   https://www.globenewswire.com/news-release/2020/10/05/2103391/0/en/Latest-Research-Evaluating-VASCEPA-Icosapent-Ethyl-Mechanisms-of-Action-Presented-at-European-Atherosclerosis-Society-EAS-Congress-2020.html     OTOH  VASCEPA is the original and genuine oil, not just a generic from small companies  is it ok!?
This result is meaningful:  https://www.globenewswire.com/news-release/2020/10/05/2103391/0/en/Latest-Research-Evaluating-VASCEPA-Icosapent-Ethyl-Mechanisms-of-Action-Presented-at-European-Atherosclerosis-Society-EAS-Congress-2020.html     OTOH: VASCEPA is the original product and proce$$,  not just a generic from small companies,   is it ok!?
...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.